The global atrial fibrillation drugs market size was valued at USD 24.59 billion in 2024 and is projected to reach from USD ...

Proactively managing atrial fibrillation is crucial for patients and healthcare providers, often necessitating the use of drugs due to the condition's propensity for severe consequences ...

(MENAFN- GlobeNewsWire - Nasdaq) The global atrial fibrillation drugs market size was valued at USD 24.59 billion in 2024 and is projected to reach from USD 27 billion in 2025 to USD 62.64 billion ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Discover how abelacimab reduces bleeding risks in AFib patients by effectively lowering free factor XI levels.

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

A 240-year-old drug called digoxin could save the National Health Service (NHS) at least £100 million each year when treating older patients with atrial fibrillation and heart failure.

A new study suggests that certain substances in the blood may help identify people with a type of irregular heartbeat called ...

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

The atrial fibrillation (AFib) detection feature on Apple Watch devices has become the first digital health technology to be qualified under a programme recently introduced by the FDA designed to ...